The present invention relates to a cyclic inhibitor of a kallikrein protease comprising or consisting of (I) the peptide (X.sup.1 (X.sup.2)(X.sup.3)R(X.sup.4)(X.sup.5)(X.sup.6)(X.sup.7)(X.sup.8)(X.sup.9)(X.sup.10)(X.sup.11) (Formula (X)), wherein (X.sup.1) is present or absent and, is preferably present, and if present, is an amino acid, and is most preferably D-alanine or G; (X.sup.2) is an amino acid with a side chain; (X.sup.3) is an amino acid with a polar uncharged side chain, is preferably with a polar uncharged side chain comprising a hydroxyl group, is more preferably T or S and is most preferably T; (X.sup.4) is an amino acid, preferably citrulline, Q or E; (X.sup.5) is an amino acid, preferably an amino acid with a hydrophobic side chain; (X.sup.6) is present or absent, is preferably absent, and, if present, is an amino acid with a negatively charged side chain, preferably D; (X.sup.7) is present or absent, is preferably present, and, if present, is an amino acid, more preferably an amino acid with a side chain comprising a pyrrole of indole, even more preferably P, hydroxyl-proline, (R)-3-piperidine carboxylic acid or W, and most preferably P; (X.sup.8) is present or absent and, if present, is an amino acid, and is preferably absent; (X.sup.9) is present or absent and, if present, is an amino acid, and is preferably absent; (X.sup.10) is an amino acid with a side chain; and (X.sup.11) is present or absent and, if present, is an amino acid, and is preferably absent; wherein the side chains of (X.sup.2) and (X.sup.10) are connected via a connecting molecule, said connecting molecule having at least two functional groups, each functional group forming a covalent bond with one of the side chains of (X.sup.2) and (X.sup.10); and wherein the kallikrein protease is Kallikrein-related peptidase (KLK5); or (II) the peptide (Y.sup.1)(Y.sup.2)(Y.sup.3) (Y.sup.4)(Y.sup.5)(Y.sup.6)(Y.sup.7)(Y.sup.8)(Y.sup.9) (Formula (Y)), wherein (Y.sup.1) is present or absent, is preferably present, and, if present, is an amino acid, preferably P, L-beta-hydroxyl-proline, D-proline, (R)-3-piperidine carboxylic acid, Q or R, and is most preferably P; (Y.sup.2) is an amino acid with a side chain; (Y.sup.3) is I, L or L-Neopentylglycine, and is preferably L; (Y.sup.4) is Y or F, and is preferably Y; (Y.sup.5) is an amino acid, preferably an amino acid with a hydrophobic side chain, or Q or R, is more preferably L, norleucine, Q, I, R or M, and is most preferably norleucine or L; (Y.sup.6) is an amino acid, preferably an amino acid with a hydrophobic side chain and is most preferably A; (Y.sup.7) is absent or present, preferably present and, if present, is an amino acid prefer

The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.

This disclosure provides SERPIN B1 polypeptides that possess neutrophil or pancreatic elastase inhibitory activity, and the elastase inhibition activity is resistant to oxidation by free radicals. The free radicals may a reactive oxygen species, or a reactive nitrogen species, or both. In some embodiments, the SERPIN B1 polypeptide comprises an amino acid substitution at residue 344 as compared to SEQ ID NO: 1. The SERPIN B1 polypeptides disclosed herein can be used to treat a patient having a disease or a genetic condition that is associated with the increased production of free radicals as compared to a normal individual or increased exposure to free radicals in environmental sources.

The present application relates to aqueous solution compositions of engineered dimeric proteins comprising monomers that comprise at least one human serpin polypeptide operably linked to a human immunoglobulin Fc polypeptide or a polypeptide that is derived from an immunoglobulin Fc polypeptide, at low buffer concentrations and low ionic strength and containing a neutral amino acid. The aqueous solution compositions increase the stability of the an Fc domain in aqueous solution compositions, and in particular increase the stability of an engineered dimeric protein.

Disclosed herein are SERPIN peptides, and analogues and derivatives thereof, and uses of the same for treating various conditions associated with LRP1 mediation.

Disclosed are biodegradable nanocarriers that have a net positive surface charge and zeta potential between about +2 to about +20 mV. The positive surface charge of the nanocarriers is provided by peptides that are covalently attached to the surface of the nanocarriers. The nanocarriers may comprise a drug and may be administered for localized and sustained delivery of the drug.

The present invention relates to a process for purifying C1-esterase inhibitor (C1-INH), and more in particular a C1-INH concentrate.

The present invention relates to methods for reducing antennary fucosylation of complex N-glycans in recombinantly expressed glycoproteins, cell lines that can be used in said methods, respective recombinant glycoproteins, and methods for expressing the same in said cell lines.

Provided herein are compositions and methods of using base editors comprising a polynucleotide programmable nucleotide binding domain and a nucleobase editing domain in conjunction with a guide polynucleotide. Also provided herein are base editor systems for editing nucleobases of target nucleotide sequences.

Disclosed herein are topical compositions for treating wounds. The topically compositions include a Serp-1 polypeptide or a nucleic acid encoding a Serp-1 polypeptide. Also disclosed are methods of treating a wound in subject. The methods include administering a topical formulation that includes a Serp-1 polypeptide or a nucleic acid encoding a Serp-1 polypeptide to the wound.